Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years

Zhenhua Ma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2203-0991; OpenAlex author ID A5115604773. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 3 papers · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 12

  1. Resveratrol inhibits pancreatic cancer proliferation and metastasis by depleting senescent tumor-associated fibroblasts. Last author DOI 10.4251/wjgo.v16.i9.3980↗
  2. An amino acid metabolism-based seventeen-gene signature correlates with the clinical outcome and immune features in pancreatic cancer. Co-author DOI 10.3389/fgene.2023.1084275↗
  3. Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway. Last author DOI 10.1002/1878-0261.12116↗
  4. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression. Last author DOI 10.1016/j.canlet.2016.10.019↗
  5. Reactive Oxygen Species and Targeted Therapy for Pancreatic Cancer. Last author DOI 10.1155/2016/1616781↗
  6. Pancreatic stellate cells contribute pancreatic cancer pain via activation of sHH signaling pathway. Last author DOI 10.18632/oncotarget.7776↗
  7. Resveratrol in the treatment of pancreatic cancer. Last author DOI 10.1111/nyas.12837↗
  8. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3069↗
  9. Hydrogen peroxide mediates hyperglycemia-induced invasive activity via ERK and p38 MAPK in human pancreatic cancer. First author DOI 10.18632/oncotarget.5045↗
  10. The Activation of β1-integrin by Type I Collagen Coupling with the Hedgehog Pathway Promotes the Epithelial-Mesenchymal Transition in Pancreatic Cancer. Co-author DOI 10.2174/1568009614666140402105101↗
  11. Effect of resveratrol on proliferation and apoptosis of human pancreatic cancer MIA PaCa-2 cells may involve inhibition of the Hedgehog signaling pathway. First author DOI 10.3892/mmr.2014.2511↗
  12. Aspirin: a potential therapeutic approach in pancreatic cancer. Co-author DOI 10.2174/09298673113209990196↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 10 shared papers, 2013–2017 · strength 0.47
  2. Zheng Wang · 5 shared papers, 2014–2024 · strength 0.45
  3. Jiguang Ma · 7 shared papers, 2014–2017 · strength 0.33
  4. Wanxing Duan · 7 shared papers, 2014–2017 · strength 0.33
  5. Xuqi Li · 7 shared papers, 2014–2017 · strength 0.32
  6. Qinhong Xu · 7 shared papers, 2013–2017 · strength 0.30
  7. Guotai Wang · 1 shared paper, 2024 · strength 0.28
  8. He Jiang · 1 shared paper, 2024 · strength 0.28
  9. MA Qing-yong · 1 shared paper, 2024 · strength 0.28
  10. Cancan Zhou · 2 shared papers, 2017–2023 · strength 0.26
  11. Erxi Wu · 5 shared papers, 2014–2017 · strength 0.23
  12. Jianjun Lei · 5 shared papers, 2014–2017 · strength 0.22
  13. Lun Zhang · 5 shared papers, 2013–2016 · strength 0.22
  14. Zhengdong Jiang · 4 shared papers, 2015–2017 · strength 0.21
  15. Jie Hao · 1 shared paper, 2023 · strength 0.20
  16. Rongqian Wu · 1 shared paper, 2023 · strength 0.20
  17. Liang Han · 4 shared papers, 2014–2017 · strength 0.18
  18. Wei Li · 3 shared papers, 2014–2016 · strength 0.15
  19. Zheng Wu · 3 shared papers, 2015–2017 · strength 0.15
  20. Liang Zong · 3 shared papers, 2015–2016 · strength 0.14
  21. Liankang Sun · 2 shared papers, 2017 · strength 0.11
  22. Jiahui Li · 2 shared papers, 2016–2017 · strength 0.11
  23. Ligang Nan · 2 shared papers, 2015–2016 · strength 0.10
  24. Ke Chen · 1 shared paper, 2017 · strength 0.06
  25. Liang Cheng · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.